Drugs / HBV mRNA vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07077356 | Aug 2025 → Dec 2026 expected | hepatocellular carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05738447 | Feb 2023 → Jan 2024 | hepatocellular carcinoma | West China Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBV mRNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05738447 ↗ |
| Modality | Messenger RNA (mRNA) | “The mRNA vaccines are a highly promising novel anti-tumor approach.” NCT05738447 ↗ |